What is HC Wainwright’s Estimate for CLDX FY2024 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Celldex Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($2.39) per share for the year, up from their previous forecast of ($2.48). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2024 earnings at ($0.66) EPS and FY2025 earnings at ($3.02) EPS.

A number of other brokerages have also commented on CLDX. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Citigroup initiated coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $27.01 on Monday. Celldex Therapeutics has a 52 week low of $24.43 and a 52 week high of $53.18. The stock has a market capitalization of $1.79 billion, a P/E ratio of -10.65 and a beta of 1.60. The stock has a fifty day moving average of $33.29 and a 200-day moving average of $35.72.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the business. Arizona State Retirement System increased its stake in Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 325 shares in the last quarter. KBC Group NV raised its holdings in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the period. Los Angeles Capital Management LLC lifted its position in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.